As shown in the recent phase 3 CASSIOPEIA trial, the clinical benefits of VTD in terms of depth of response, rate of measurable residual disease (MRD) negativity and progression-free survival (PFS) can be further enhanced by the addition of daratumumab, a first-in-class monoclonal antibody targeting CD38, i.e., an antigen commonly expressed on the surface of MM cells [45]. The gene discussed is CD38; the disease is Miyoshi myopathy.